Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ThredUp Inc (TDUP) Price & Performance

ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.

Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.

ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.

The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.